Review Article

Research Progress on Lympho Proliferative Diseases after Lung Transplantation

Yue Ma, Jun Chen*
Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, China

Received: August 03, 2018; Published: August 13, 2018

*Corresponding author: Jun Chen, Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China

Abstract

With the development of surgical methods and pharmaceutical preparations, more patients with benign end-stage lung disease can receive treatment of lung transplants. Not only the number of surgeries has increased to 4,000 per year, but also the survival time has been growing longer. Ten years ago, a lot of medical experts thought that post-transplant lymphoproliferative disease was a rare disease, but this disease has received more and more attention because of increasing of surgeries. PTLD is a serious and rare post-transplant complication. Compared with other organ transplants, the incidence of heart, lung, and heart lung transplantation is extremely high. The 5-year survival rate is 29%, and the median survival period is 10 months. Risk factors for morbidity are related to the use of immunosuppressive agents, viral infections, type of transplanted organ, gender, age et al. This article will describe the incidence, risk factors, pathogenic mechanism, treatment methods and latest research progress of lymphoproliferative diseases after lung transplantation recently by providing new ideas on hotspots.

Keywords: Lung Transplantation; Post Transplant Lymphoproliferative Disorders; Immunosuppressants; Viral Infection

Introduction

Lung transplantation is the only effective way to treat benign lung disease of end-stage. Vladimir performed lung transplant surgery on animals for the first time 70 years ago epically [1]. Soon after, Hardy did the first human lung transplantation 12 years later [2]. But patient only lived 42 days after the transplant by limiting to the development of surgical techniques and drugs. The emergence of immunosuppressants represented by cyclosporine (CsA) in 1983 significantly pulled the survival rate after lung transplantation to a new level. Afterwards, the median survival time after transplantation can reach 5.3 years [3]. Nowadays there are about 4,000 lung transplants per year, including 200 in China. Most of medical experts initially thought that Post-transplant lymphoproliferative disorders (PTLD) was a rare disease, which was been known as a mega misunderstanding presently by discovering from the results of research in the last decade and the increase in surgical patients as well. Immunosuppression and Epstein-Barr virus (EBV) infection are two the most relevant risk factors about PTLD [4]. This article will elaborate advances in research on post-transplant lymphoproliferative disorders after lung transplantation in recent years and put forward prospects at the same time.

Lung Transplantation Indications and Common Complications

Lung transplant indications are generally benign lung disease of end-stage, such as advanced chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis, diffuse resistance bronchial expansion, et cetera. Usually clinicians do not recommend lung transplant surgery for lung cancer patient. According to many factors like age, disease type, disease progression, and various causes of underlying diseases, lung transplantation can be divided into double lung transplantation, single lung transplantation, combined heart and lung transplantation, and lobar transplantation. Toronto General Hospital, which has the largest volume of lung transplants in the world, only considers single-lung transplantation when one-sided lung tissue cannot be used. The median survival of patients undergoing double lung transplantation is significantly higher than that of single lung transplantation. 50.4 months (P < 0.05) [5]. Common complications after lung transplantation include reperfusion pulmonary edema, pulmonary infection, acute rejection, chronic rejection, anastomotic stricture, pneumothorax and pleural effusion. However, malignant tumors after lung transplantation are relatively rare [6-8].

Post transplant Lymphoproliferative Disorders

Epidemiology of PTLD

PTLD is substantial lymphocyte proliferation which generally occurs in solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT) (heterologous). Epidemiology is related to many factors. PTLD occurs after SOT is more common in the use of immunosuppressive agents, EBV infection, transplantation of
organisms such as heart and lungs; PTLD occurs after HSCT is more common in the lack of human leukocyte antigen matching. The incidence of PTLD after kidney transplantation was the lowest (0.8-2.5%), then increase in order by pancreas transplantation (0.5-5.0%), liver transplantation (1.0%-5.5%), heart transplantation (2.0%-8.0%), lung transplantation (3.0%-10.0%), multiple organs or intestines transplantation (≥20%). The incidence of PTLD after heart, lung, and heart-lung transplantation is extremely high, with a five-year survival rate of 29% and median survival time of 10 month [9-10]. The incidence of PTLD after lung transplantation in children is even as high as 17.6% [11]. Lung is the only organ that can perform oxygen exchange without relying on blood perfusion. Not only respiratory organs, but also an immune organ, which may be related to the high incidence of PTLD. One research showed that the incidence of PTLD in SOT and HSCT don't have significant difference. However, PTLD patients have lower survival rate and faster disease progresses after HSCT [12].

Clinical Performance and Auxiliary Examination

PTLD has a variety of clinical manifestations, such as fever, fatigue, swollen tonsils, surface lymphadenopathy and relative organ symptoms, which can develop into multiple organ failure in days. Nodular lesion (83%) and diffuse large b-cell lymphoma (72%) are the most common manifestations. Involvement of bone marrow and central nervous system is uncommon (<13%). Bone marrow infiltration, low serum albumin value (<30g/L), halo sign in chest computed tomography (CT) and late-onset PTLD are the bad sign of prognosis [13]. Usually in chest CT, PTLD presents multiple pulmonary nodules in the periphery and bottom of the lung which have clear boundaries and generally lack of bronchial gas phase and necrosis [14]. In 2017, World Health Organization classified PTLD pathological types into six categories: 1. nondestructive PTLD: plasmacytic hyperplasia; 2. nondestructive PTLD: infectious mononucleosis-like PTLD; 3. nondestructive PTLD: florid follicular hyperplasia; 4. polymorphic PTLD; 5. monomorphic PTLD; 6. classic Hodgkin’s lymphomas [15-16]. The clinical symptoms of PTLD and the graft-versus-host response (GVHD) are easily confused with one another. Early pathological biopsy is recommended if it is possible.

Depletion of Immune Cells

In the short term after lung transplantation, large doses of immunosuppressive agents and hormones are required during the induction period to suppress acute rejection. This action can lead the incidence rate drop to 13.3% [17]; mostly oral immunosuppression to maintain effect in long term. The anti-rejection effect of immunosuppressive agents was significant, but the depletion of T-lymphocytes became a risk factor for PTLD (RR: 8.4-15.8%). Triple immunosuppressive agents (tacrolimus, mycophenolate mofetil, prednisone) are the recommended program in maintenance phase. Tacrolimus was used in 83% of patients within 1 year after lung transplantation and 77% of patients within 5 years, unfortunately it has been shown to be an independent risk factor for the development of PTLD [18-19]. Some researchers have found that the occurrence of non-Hodgkin’s lymphomas might be related to the production of abnormal NK cells. The expression of specific activated receptors NKp30, NKp46, and NKG2D value are low. Perforin expression is drastically reduced, and immunosuppressive agents have nothing to do with it [20].

Viral Infection

PTLD lesions mostly originate from EBV-infected B-lymphocytes, and if immune system can‘t defeat it, it will turn into tumor cells. EBV (+) patients have at least 4 times increase in PTLD after transplantation, especially in patients with early-onset [21]. About 30% of EBV (+) PTLD patients have tonsil swelling, but it often means benign lesions [22]. Young patients are likely to manifest as swollen lymph nodes in neck, yet older patients are likely to manifest as pulmonary nodules [22]. EBV positive is not a diagnostic basis, similarly, measuring EBV viral load in peripheral blood does not aid diagnosis. However, EBV-encoded RNA in situ hybridization test is recommended in clinical practice [23]. Patients with cystic fibrosis have a higher risk of EBV (+) and CMV(+), which could lead to PTLD [24]. Cytomegalovirus (CMV) infection is the most serious viral infection after transplantation, and the guide recommends routine use of ganciclovir for 6-9 months during the perioperative period.

Treatment Plan

There are many clinical methods for the treatment of PTLD, including reducing the use of immunosuppressive agents, surgery, radiotherapy, chemotherapy, monoclonal antibody therapy, and antiviral therapy et cetera. Limiting and complete marginal lesions are mainly surgically removed; The effect of antiviral treatment is not clear yet and should be used as adjuvant therapy. The pulmonary nodules that were found after transplantation were to determine the quality of the disease. PET-CT was recommended and the accuracy was as high as 86% [25], but local radiotherapy was not highly recommended [26].

a. Reduce the use of immunosuppressive agents: reducing the half dosage of calcineurin inhibitors and discontinuing unnecessary dose of glucocorticoid or anti-tumor meta advantages metabolism drugs could drop the incidence of PTLD by 20-80%. Clinicians should weigh the and disadvantages about immunosuppressive agents, which should not cause a strong rejection, like GVHD. One research has pointed out the routine use of R-CHOP does not increase the incidence of PTLD without using CsA [27]. 179 patients who underwent lung transplant surgery in Japan during period 2001-2010. 18 patients of it developed malignant tumors (PTLD, 12 cases), and 14 patients were controlled after reducing or stopping the use of immunosuppressive agents [28]. Unfortunately, one research has showed that mortality rate of PTLD patients were still 50% even after reducing immunosuppressive agents [29];

b. Rituximab: usually it came after with failure of reducing immunosuppressive agents. We recommend 375 mg/m3. Complete remission rate fluctuates at 20%-55%. In addition, increasing the dosage of rituximab will also have a positive effect on the remission rate, especially on CD 20 (+) PTLD patients [29-31]. Rituximab can be even at first-line therapy for PTLD [32];
c. Chemotherapy: The use of chemotherapeutic agents is generally used in patients with PTLD-based lymphomas, or after the ineffectiveness of the above two treatment options. CD20 (+) patients can add rituximab.

d. Re-transplantation: Its incidence is 2.4%. Early re-transplantation (within 1 month), male donor, and renal insufficiency are the bad sign of prognosis [33]. The second transplantation should be 1 year later from the PTLD treatment.

References


